Clinical-sonographic scores for the screening of placenta accreta spectrum: A systematic review and meta-analysis.

Placenta accreta spectrum cesarean delivery meta-analysis scores systematic review ultrasound imaging

Journal

American journal of obstetrics & gynecology MFM
ISSN: 2589-9333
Titre abrégé: Am J Obstet Gynecol MFM
Pays: United States
ID NLM: 101746609

Informations de publication

Date de publication:
16 Apr 2024
Historique:
received: 04 11 2023
revised: 14 03 2024
accepted: 01 04 2024
medline: 19 4 2024
pubmed: 19 4 2024
entrez: 18 4 2024
Statut: aheadofprint

Résumé

Clinical-sonographic scoring systems, combining clinical features and ultrasound imaging markers have been proposed for the screening of placenta accreta spectrum (PAS) but their usefulness in different set-ups remains limited. The aim of this study was to assess and compare different clinical-sonographic score systems performed from the midst of pregnancy for the prenatal evaluation of patients at risk of PAS at birth. PubMed/MEDLINE, Google Scholar, and Embase were searched between October 1982 and October 2022 to identify eligible studies. Observational studies providing data on the use of a combined clinical-ultrasound score systems performed from the midst of pregnancy for the prenatal evaluation of PAS. Study characteristics were evaluated by two independent reviewers using a predesigned protocol PROSPERO (CRD CRD42022332486). Heterogeneity between studies was analysed with Cochran's Q-test and the I Of 1028 articles reviewed, 12 cohorts and two case-control studies including 1630 patients screening for PAS by clinical-ultrasound scores met the eligibility criteria. A diagnosis of PAS was reported in 602 (36.9%) cases for which 547 (90.9%) intraoperative findings and/or histopathologic data were described. A wide variation in reported sensitivities and specificities was observed between studies and in thresholds used for the identification of patients with a high probability of PAS at birth. The SAUCs of the individual sonographic scores ranged between 0.85 (the lowest) for sub-placental hypervascularity to 0.91 for placental location in the lower uterine segment (LUS), myometrial thinning, and placental lacunae and 0.95 for the loss of clear zone. Only four studies included placental bulging in their sonographic score system and therefore no meta-analysis for this score was performed. The integrated SAUC was 0.83 [95% Confidence Interval (95% CI) 79 to 0.86). Forest Plot analysis revealed an integrated sensitivities and specificities of 0.68 [95% CI 0.53-0.80], and 0.88 [95% CI 0.68 to 0.96]), respectively. Clinical-sonographic score systems can contribute to the prenatal screening of patients at risk of PAS at birth. While we included multiple sonographic studies from the midst of pregnancy, standardized evaluation should be performed not only with strict ultrasound criteria for the placental position, mid third trimester gestational age at examination, and sonographic markers associated with PAS. Numeric sensitivities, specificities, NPVs, PPV, LR-, and LR+ should be recorded prospectively to assess their accuracy in different set-ups and PTP should be verified at delivery. The variables recommended for most predictive screening are: loss of clear zone underneath the placental bed, placentation in the LUS, and placenta lacunae.

Identifiants

pubmed: 38636601
pii: S2589-9333(24)00095-8
doi: 10.1016/j.ajogmf.2024.101369
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

101369

Informations de copyright

Copyright © 2024. Published by Elsevier Inc.

Déclaration de conflit d'intérêts

Conflict of interest The authors report no conflict of interest in relation to the content of this paper. Conflict of interest The authors report no conflict of interest. Dr. Meiri is the CEO and Director of TeleMarpe Ltd, but the company has no IP and it does not hold any security in relation to the content of this paper.

Auteurs

Marina Pekar Zlotin (MP)

Department of Obstetrics and Gynecology, The Yitzhak Shamir Medical Center (formerly Assaf Harofeh Medical Center), Zerifin, 7033001. Israel, and the School of Medicine, Faculty of Medical and Health Sciences, Tel-Aviv University, Tel-Aviv, Israel.

Adi Sharabi-Nov (A)

Department of Statistics, Tel Hai Academic College, Tel Hai 12210, and Ziv Medical Center, Safed 13100, Safed.

Hamutal Meiri (H)

PreTwin Screen Consortium and TeleMarpe Ltd, 41 Beit El Street, Tel Aviv, 6908742, Israel.

Perry Eliassi Revivo (PE)

Department of Obstetrics and Gynecology, The Yitzhak Shamir Medical Center (formerly Assaf Harofeh Medical Center), Zerifin, 7033001. Israel, and the School of Medicine, Faculty of Medical and Health Sciences, Tel-Aviv University, Tel-Aviv, Israel.

Yakkov Melcer (Y)

PreTwin Screen Consortium and TeleMarpe Ltd, 41 Beit El Street, Tel Aviv, 6908742, Israel.

Ron Maymon (R)

Department of Obstetrics and Gynecology, The Yitzhak Shamir Medical Center (formerly Assaf Harofeh Medical Center), Zerifin, 7033001. Israel, and the School of Medicine, Faculty of Medical and Health Sciences, Tel-Aviv University, Tel-Aviv, Israel. Electronic address: maymonrb@bezeqint.net.

Eric Jauniaux (E)

EGA Institute for Women's Health, Faculty of Population Health Sciences, University College London (UCL), London, UK.

Classifications MeSH